MedCap AB (MCAP) AI Stock Analysis

• Market Cap: kr6.07B
• Dividend Yield: N/A
• Average Volume (3M): 26.11K
• Price to Earnings (P/E): 28.9
• Beta (1Y): 0.39
• Revenue Growth: 13.82%
• EPS Growth: 20.38%
• Country: SE
• Employees: 368
• Sector: Healthcare
• Sector Strength: 65
• Industry: Asset Management Services
• EPS (TTM): 13.99
• Shares Outstanding: 14,981,353
• 10 Day Avg. Volume: 19,741
• 30 Day Avg. Volume: 26,115
• PEG Ratio: 1.42
• Price to Book (P/B): N/A
• Price to Sales (P/S): N/A
• Price to Cash Flow (P/CF): N/A
• P/FCF Ratio: N/A
• Enterprise Value/Market Cap: N/A
• Enterprise Value/Revenue: N/A
• Enterprise Value/Gross Profit: N/A
• Enterprise Value/Ebitda: N/A
• 1Y Price Target: N/A
• Price Target Upside: N/A
• Rating Consensus: N/A
• Number of Analyst Covering: 0

MedCap AB's overall stock score reflects its robust financial performance, characterized by strong revenue growth, efficient operations, and solid cash flow generation. However, the technical analysis indicates a bearish trend, with the stock trading below major moving averages, which poses short-term risks. The valuation is reasonable, though the absence of a dividend yield might deter some investors. Overall, MedCap AB presents a well-balanced investment opportunity with both strengths and areas to monitor.

MedCap AB Business Overview & Revenue Model

Company Description

MedCap AB (MCAP) is a Sweden-based investment company that specializes in acquiring and developing small to medium-sized enterprises within the life sciences sector. The company focuses on businesses with significant growth potential in pharmaceuticals, biotechnology, medical technology, and healthcare services. MedCap leverages its industry expertise to enhance the value of its portfolio companies, driving innovation and operational improvements.

How the Company Makes Money

MedCap AB makes money primarily through the acquisition and development of companies in the life sciences sector. The company invests in businesses with potential for growth and profitability, and then works to improve their operational efficiencies and market positions. Revenue is generated through the appreciation of these investments, allowing MedCap to realize profits when these companies are sold or go public. Additionally, MedCap may earn income through dividends and distributions from its portfolio companies. Strategic partnerships and the careful selection of high-potential businesses are significant factors that contribute to the company's earnings.

MedCap AB Financial Statement Overview

Summary

Income Statement

Balance Sheet

Cash Flow

Breakdown
Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Income Statement		Total Revenue
1.81B	1.59B	1.11B	916.30M	817.40M
	Gross Profit
1.06B	926.40M	462.40M	369.80M	326.60M
	EBIT
272.30M	227.50M	170.90M	127.00M	89.10M
	EBITDA
396.00M	327.40M	237.30M	186.80M	147.80M
	Net Income Common Stockholders
207.40M	172.20M	117.60M	96.50M	60.90M
Balance Sheet		Cash, Cash Equivalents and Short-Term Investments
370.10M	188.20M	236.20M	139.70M	146.50M
	Total Assets
1.99B	1.66B	1.43B	1.17B	1.08B
	Total Debt
358.00M	261.20M	340.00M	256.90M	263.70M
	Net Debt
-12.10M	73.00M	103.80M	117.20M	117.20M
	Total Liabilities
703.20M	635.10M	570.60M	471.80M	479.30M
	Stockholders Equity
1.28B	1.02B	856.30M	696.00M	595.70M
Cash Flow		Free Cash Flow
293.80M	188.70M	41.20M	55.40M	91.20M
	Operating Cash Flow
360.00M	228.00M	85.50M	116.30M	115.60M
	Investing Cash Flow
-128.80M	-152.30M	-56.10M	-64.80M	-131.90M
	Financing Cash Flow
-46.10M	-119.70M	61.20M	-64.10M	144.50M

MedCap AB Technical Analysis

• Technical Analysis Sentiment: Neutral
• Last Price: 392.50
• 50DMA: Positive
• 100DMA: Negative
• 200DMA: Negative
• MACD: Negative
• RSI: Neutral
• STOCH: Negative

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For SE:MCAP, the sentiment is Neutral. The current price of 392.5 is above the 20-day moving average (MA) of 360.73, above the 50-day MA of 373.60, and below the 200-day MA of 490.46, indicating a neutral trend. The MACD of 2.86 indicates Negative momentum. The RSI at 61.70 is Neutral, neither overbought nor oversold. The STOCH value of 94.65 is Negative, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Neutral sentiment for SE:MCAP.

MedCap AB Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
BURE	73 Outperform	€21.52B	3.75	26.07%	0.81%	1.45%	21.01%
MCAP	71 Outperform	kr6.07B	28.95	17.78%	―	13.82%	20.38%
SVOL.B	64 Neutral	kr5.64B	12.68	7.27%	3.15%	―	―
IDUN.B	59 Neutral	kr3.94B	121.49	5.82%	0.26%	6.27%	6.15%
LINC	57 Neutral	kr3.78B	3.03	5.76%	―	37.32%	-39.07%
Sector *	51 Neutral	$5.31B	3.33	-39.82%	2.92%	17.95%	1.84%